Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 99

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

In Vitro Pharmacological Characterization of Vilanterol, a Novel Long-Acting β2-Adrenoceptor Agonist with 24-Hour Duration of Action

Slack, Robert J., Barrett, Victoria J., Morrison, Valerie S., Sturton, Richard G., Emmons, Amanda J., Ford, Alison J., Knowles, Richard G. · 2013 · The Journal of Pharmacology and Experimental Therapeutics

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1124/jpet.112.198481

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 38

  1. Anderson, 1993, Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilator, Life Sci, 52, 2145, 10.1016/0024-3205(93)90729-M · DOI · Paper page
  2. Anderson, 1994, Why are long-acting beta-adrenoceptor agonists long-acting?, Eur Respir J, 7, 569, 10.1183/09031936.94.07030569 · doi:10.1183/09031936.94.07030569
  3. Baker, 2005, The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors, Br J Pharmacol, 144, 317, 10.1038/sj.bjp.0706048 · DOI · Paper page
  4. Baker, 2010, The selectivity of β-adrenoceptor agonists at human β1-, β2- and β3-adrenoceptors, Br J Pharmacol, 160, 1048, 10.1111/j.1476-5381.2010.00754.x · DOI · Paper page
  5. Ball, 1991, Salmeterol, a novel, long-acting β2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo, Br J Pharmacol, 104, 665, 10.1111/j.1476-5381.1991.tb12486.x · DOI · Paper page
  6. Battram, 2006, In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled β2 adrenoceptor agonist with a 24-h duration of action, J Pharmacol Exp Ther, 317, 762, 10.1124/jpet.105.098251 · DOI · Paper page
  7. Broadley, 2006, β-adrenoceptor responses of the airways: for better or worse?, Eur J Pharmacol, 533, 15, 10.1016/j.ejphar.2005.12.060 · DOI
  8. Busse, 2001, Asthma, N Engl J Med, 344, 350, 10.1056/NEJM200102013440507 · DOI · Paper page
  9. Casarosa, 2011, Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol, J Pharmacol Exp Ther, 337, 600, 10.1124/jpet.111.179259 · doi:10.1124/jpet.111.179259
  10. Cazzola, 2011, β2-adrenoceptor agonists: current and future direction, Br J Pharmacol, 163, 4, 10.1111/j.1476-5381.2011.01216.x · DOI · Paper page
  11. Cazzola, 2010, The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD, Pulm Pharmacol Ther, 23, 257, 10.1016/j.pupt.2010.03.003 · DOI · Paper page
  12. Celli, 2004, Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper, Eur Respir J, 23, 932, 10.1183/09031936.04.00014304 · DOI · Paper page
  13. Cheng, 1973, Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction, Biochem Pharmacol, 22, 3099, 10.1016/0006-2952(73)90196-2 · DOI · Paper page
  14. Coleman, 1996, Exosites: their current status, and their relevance to the duration of action of long-acting β2-adrenoceptor agonists, Trends Pharmacol Sci, 17, 324, 10.1016/0165-6147(96)10040-7 · DOI
  15. Contreras, 1986, Thermodynamic properties of agonist interactions with the beta adrenergic receptor-coupled adenylate cyclase system. I. High- and low-affinity states of agonist binding to membrane-bound beta adrenergic receptors, J Pharmacol Exp Ther, 237, 154, 10.1016/S0022-3565(25)24907-2 · DOI
  16. Cullum, 1969, Salbutamol: a new, selective β-adrenoceptive receptor stimulant, Br J Pharmacol, 35, 141, 10.1111/j.1476-5381.1969.tb07975.x · DOI · Paper page
  17. Hanania, 2012, The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial, Chest, 142, 119, 10.1378/chest.11-2231 · doi:10.1378/chest.11-2231
  18. Hill, 1909, The mode of action of nicotine and curari, determined by the form of the contraction curve and the method of temperature coefficients, J Physiol, 39, 361, 10.1113/jphysiol.1909.sp001344 · DOI · Paper page
  19. Hirst, 2010, Use of long-acting β-agonists and inhaled steroids in asthma: meta-analysis of observational studies, J Asthma, 47, 439, 10.3109/02770901003605340 · doi:10.3109/02770901003605340
  20. Holm, 1979, A simple sequentially rejective multiple test procedure, Scand J Stat, 6, 65
  21. Johnson, 2002, Heterotrimeric G protein signaling: role in asthma and allergic inflammation, J Allergy Clin Immunol, 109, 592, 10.1067/mai.2002.122636 · DOI
  22. Johnson, 1993, The pharmacology of salmeterol, Life Sci, 52, 2131, 10.1016/0024-3205(93)90728-L · DOI
  23. Kardos, 2006, Tackling COPD: a multicomponent disease driven by inflammation, Med Gen Med, 8, 54
  24. Lotvall, 2012, 24h duration of the novel LABA vilanterol trifenatate in asthma patients treated with ICSs, Eur Respir J, 40, 570, 10.1183/09031936.00121411 · DOI
  25. Malerba, 2012, Therapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspects, Drug Discov Today, 17, 496, 10.1016/j.drudis.2011.11.002 · doi:10.1016/j.drudis.2011.11.002
  26. Nelson, 2006, The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol, Chest, 129, 15, 10.1378/chest.129.1.15 · DOI · Paper page
  27. Patel, 2011, The reassertion profiles of long acting β2-adrenoceptor agonists in the guinea pig isolated trachea and human recombinant β2-adrenoceptor, Pulm Pharmacol Ther, 24, 247, 10.1016/j.pupt.2010.11.004 · doi:10.1016/j.pupt.2010.11.004
  28. Procopiou PA, Barrett VJ, Bevan NJ, Biggadike K, Box PC, Butchers PR, Coe DM, Conroy R, Emmons A, Ford AJ et al. (2010) Synthesis and structure-activity relationships of long-acting β2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem 53:4522–4530. · doi:10.1021/jm100326d
  29. Rosethorne, 2010, Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled β2-adrenoceptor agonists, Naunyn Schmiedebergs Arch Pharmacol, 382, 255, 10.1007/s00210-010-0533-6 · doi:10.1007/s00210-010-0533-6
  30. Samama, 1993, A mutation-induced activated state of the β2-adrenergic receptor. Extending the ternary complex model, J Biol Chem, 268, 4625, 10.1016/S0021-9258(18)53442-6 · DOI · Paper page
  31. Smith, 1985, Measurement of protein using bicinchoninic acid, Anal Biochem, 150, 76, 10.1016/0003-2697(85)90442-7 · DOI · Paper page
  32. Sturton, 2008, Pharmacological characterization of indacaterol, a novel once daily inhaled β2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices, J Pharmacol Exp Ther, 324, 270, 10.1124/jpet.107.129296 · DOI
  33. Summerhill, 2008, A cell-based assay to assess the persistence of action of agonists acting at recombinant human β2 adrenoceptors, J Pharmacol Toxicol Methods, 58, 189, 10.1016/j.vascn.2008.06.003 · DOI
  34. Szczuka, 2009, Molecular mechanisms for the persistent bronchodilatory effect of the β2-adrenoceptor agonist salmeterol, Br J Pharmacol, 158, 183, 10.1111/j.1476-5381.2009.00296.x · doi:10.1111/j.1476-5381.2009.00296.x
  35. Tashkin, 2005, Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease?, Curr Opin Pulm Med, 11, 121, 10.1097/00063198-200503000-00004 · DOI
  36. Toews, 1983, High-affinity binding of agonists to β-adrenergic receptors on intact cells, Proc Natl Acad Sci USA, 80, 3553, 10.1073/pnas.80.12.3553 · DOI
  37. Waldeck, 2002, β-adrenoceptor agonists and asthma—100 years of development, Eur J Pharmacol, 445, 1, 10.1016/S0014-2999(02)01728-4 · DOI · Paper page
  38. Wallace, 1983, Temperature dependence of the binding of [3H]mepyramine and related compounds to the histamine H1 receptor, Mol Pharmacol, 23, 60, 10.1016/S0026-895X(25)14230-2 · doi:10.1016/s0026-895x(25)14230-2

Cited by

See all 99

Metadata

Authors
Slack, R. J., Barrett, V. J., Morrison, V. S., Sturton, R. G., Emmons, A. J., Ford, A. J., & Knowles, R. G.
Venue
The Journal of Pharmacology and Experimental Therapeutics
Publisher
Elsevier BV
Published
2013-01
Volume
344
Issue
1
Pages
218-230
ISSN
0022-3565
Cited by
99
References
1
Language
en
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In Vitro Pharmacological Characterization of Vilanterol, a Novel Long-Acting β2-Adrenoceptor Agonist with 24-Hour Duration of Action. https://app.cochat.ai/papers/10.1124/jpet.112.198481
The paper
Slack, R. J., Barrett, V. J., Morrison, V. S., Sturton, R. G., Emmons, A. J., Ford, A. J., & Knowles, R. G. (2013). In Vitro Pharmacological Characterization of Vilanterol, a Novel Long-Acting β2-Adrenoceptor Agonist with 24-Hour Duration of Action. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.112.198481

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.